Upgrade to SI Premium - Free Trial

Goldman Sachs Resumes AbCellera Biologics (ABCL) at Neutral

September 24, 2026 4:59 AM
(Updated - September 24, 2026 5:32 AM EDT)

Goldman Sachs analyst Andrea Newkirk resumes coverage on AbCellera Biologics (NASDAQ ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments New Coverage